Read Gene

Read Gene Earnings Yield

The Earnings Yield of Read Gene (RDG.WA) as of Oct 21, 2026 is 0.16 %. In the previous year, Earnings Yield was -1.81 % — a change of -108.72% (higher).

Earnings Yield

0.16 %

YoY

-108.72%

Last updated:

Earnings Yield of Read Gene is 2025 0.16 % . Earnings Yield of Read Gene was 2024 -1.81 % . It decreases by -108.72% higher compared to the previous year.

The Read Gene Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2018
1.49 PLN
Jan 1, 2019
-0.12 PLN
Jan 1, 2020
0.37 PLN
Jan 1, 2021
0.06 PLN
Jan 1, 2022
0.35 PLN
Jan 1, 2023
-2.20 PLN
Jan 1, 2024
-1.81 PLN
Jan 1, 2025
0.16 PLN
The Read Gene Earnings Yield history
YEAREarnings YieldYoY
0.16 %-108.72%
-1.81 %-17.49%
-2.20 %-731.52%
0.35 %+462.82%
0.06 %-83.26%
0.37 %-395.77%
-0.12 %-108.40%
1.49 %-2,203.69%
-0.07 %-91.23%
-0.81 %-27.04%
-1.10 %-13.22%
-1.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Earnings Yield of Read Gene is 0.16 % in 2025.

Earnings Yield of Read Gene changed from -1.81 % to 0.16 %, representing a -108.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Read Gene since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Read Gene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Read Gene

All Key Metrics — Read Gene